

Disclosure

I have no relevant conflicts of interest to disclose.

I am not a member of AAPM TG-218.



IMRT QA is a hot topic









1. Dose Distribution Comparisons

- Dose difference test
- DTA test
- Gamma test



1. Dose Distribution Comparisons

Dose difference test

• Definition:

The dose difference test is the most straightforward test to understand and interpret. The dose difference at location (\vec{r}) is the numerical difference δ between the evaluated dose $D_e(\vec{r})$ and the reference dose $D_r(\vec{r})$ at that location. Mathematically, the dose difference can be written as

 $\delta(\vec{r}) = D_e(\vec{r}) - D_r(\vec{r})$

DTA test

Gamma test



1. Dose Distribution Comparisons

Dose difference test

- Definition: $\delta(\vec{r}) = D_r(\vec{r}) D_r(\vec{r})$
- · Faces challenges if dose distribution grid sizes are different
- · Does well in low-dose gradient regions, but not in steep dose gradients
- · Doesn't account for spatial tolerance, but we need to consider it

DTA test

Gamma test



1. Dose Distribution Comparisons

Dose difference test

DTA test

- · Definition: "for a point in the reference distribution, [the DTA is] the closest location in the evaluated dose distribution with the same dose" OR: "the closest distance of the evaluated distribution isodose line"
- · Ideal for steep dose gradients, but oversensitive in low-dose gradients

Gamma test



1. Dose Distribution Comparisons

- Dose difference test
- DTA test
- Gamma test
 - · Aims to combine aspects of both above tests Definition: The displacement between two points, r
 ⁻
 _r and r
 ⁻
 _c in the reference and evaluated distributions, respectively, in the renormalized methods.

minimum displacement was defined as y

 $\gamma(\vec{r}_r) = \min\{\Gamma(\vec{r}_e, \vec{r}_r)\} \forall \{\vec{r}_e\}$

malized space was termed y,

- ΔD ΔD . Δd
- $\Delta D_{\rm r} =$ Tolerance error for dose, e.g., 3%

 $\Gamma(\vec{r}_e, \vec{r}_r) = \sqrt{\frac{r^2(\vec{r}_e, \bar{r}_r)}{\Delta d^2}} + \frac{\delta^2(\vec{r}_e, \bar{r}_r)}{\Delta D^2}$





2



1. Dose Distribution Comparisons

- Dose difference test
- DTA test
- Gamma test
 - · Aims to combine aspects of both above tests
 - Definition: $\gamma = \min\left(\sqrt{\left(\frac{\Delta D}{\Delta D_t}\right)^2 + \left(\frac{\Delta d}{\Delta d_t}\right)^2}\right)$
 - Things to consider:
 - It is universal
 - Spatial resolution
 - Interpretation



1. Dose Distribution Comparisons

Additional Considerations:

- · Dose threshold:
 - Exclude the low-dose (10%) areas from analysis
- Normalization options:
 - Use global normalization versus local normalization
- System performance:
 - Clinical case sent to vendors with varying results- why?





3. Tolerance & Action Limits

Definitions

- The **Tolerance Limit** refers to the range within which the IMRT QA process is considered to be unchanging.
- The <u>Action Limit</u> sets a minimum level of process performance such that IMRT QA measurements outside the action limits could result in a negative clinical impact for the patient.



3. Tolerance & Action Limits

What should we use?

- Tolerance Limit: 95%
- Action Limit: 90%

Where do these limits come from?

- · Used statistical process control methods to develop
- In agreement with paper by Stambaugh et al.





4. Courses of Action

What happens when your QA fails?

- · Check your setup.
- Check for correct file transfer.
- Is anything deviating from normal? Check daily QA. Validate dose calibration with a standard dose (recommended prior to each PSQA).
- Determine where the failed points are. Are they relevant to the plan? Are they clustered in one area?
- Try to isolate the discrepancy, such as by performing a PFF analysis.



4. Courses of Action

Regarding overall PSQA process:

- · Track your results.
 - · May reveal trends for specific sites.
 - May indicate room for improvement in other areas of QA process.
 - Stambaugh et al. (Dec. 2018), "Improvements in treatment planning calculations motivated by tightening IMRT QA tolerances"
- Move toward structure-by-structure or DVH-based analysis.



Summary

- 1. Dose Distribution Comparisons • Use Gamma analysis, 3%/2 mm
- 2. Delivery Methods
 - True Composite (TC) if possible
- 3. Tolerance & Action Limits
 - TL: 95%, AL: 90%
- 4. Courses of Action
- check setup, evaluate location of failures, file transfer...
 look for trends in results, keep improving process!

"γ tool should be used as an indicator of problems, not as a single indicator of plan quality." (M. Miften, PPT)

"No single dose comparison tool provides all of the information necessary to quantitatively evaluate or compare dose distributions. Each tool has limitations that need to be understood when conducting evaluations." (TG-120)





Using TG-218 in the Clinic

Methods:

- Delivered 110 patient-specific IMRT/VMAT QA plans (with) →
- Recorded passing rates for
- 3% / 3mm and 3% / 2mm - Retrospectively delivered 15 static-beam IMRT QA plans

with TC delivery method

Static-beam IMRT QA



VMAT QA



Using TG-218 in the Clinic

			P			
Roculte	Case	Site	3%/3mm	3%/2mm	3%/3mm	3%/2mm
nesuits.		H&N	99.4	96.6	99.9	99.7
		H&N	97.9	96.8	94.9	89.9
		Prostate	98.0	95.2	98.4	97.0
		H&N	99.6	97.0	100	99.8
	5	Prostate	91.6	77.9	98.9	98.3
		H&N	99.0	97.9	99.3	98.2
		Pelvis	99.8	98.6	99.7	99.3
	8	H&N	99.6	98.7	99.6	99.0
		Prostate	99.4	99.4	99.5	98.3
		Lung	99.4	98.8	99.9	99.6
		H&N	99.7	99.2	99.8	99.7
		Esophagus	100	99.8	94.3	91.8
		Vulva	99.0	98.0	99.3	96.7
	14	H&N	100	99.5	99.9	99.6
	15	Lung	100	100	97.5	96.3

Average passing rates PC: 98.4% ($\sigma = 1.4\%$) TC: 97.6% (*σ* = 3.0%)



Case Site T T Passes 1 HBN 92,4 96,6 99,9 99,7 2 HBN 97,9 96,8 94,9 89,9 -3σ 3 Prostate 98,0 95,2 98,4 97,9 9 -5 4 HBN 99,6 97,7 98,9 98,3 -5 -5 5 Prostate 91,6 77,7 98,9 98,3 -5 -10 7 Perivis 99,8 98,7 99,0 -15 -10 -5 9 Prostate 94,4 99,0 99,0 99,0 -15 -10 10 Ung 99,4 99,4 99,5 99,3 -2σ -2σ 11 HBN 90,7 99,2 98,8 99,7 -36 -2σ 11 HBN 99,4 99,5 99,3 96,5 -2σ -2σ 12 Ecophagus 10 Ung -6 -6 -6 -6 11 HBN 100<					c	1				3	15
I HBN 99.4 96.6 99.9 99.7 2 HBN 97.9 96.8 94.9 89.9 -3σ 3 Prostate 98.0 95.2 98.4 97.0 4 HBN 99.6 97.7 98.9 98.3 5 Prostate 91.6 77.9 98.9 98.3 6 HBN 99.6 97.7 99.3 98.2 7 Pevictor 98.6 99.7 99.3 98.2 7 Pevictor 98.6 99.7 99.3 98.2 9 Prostate 91.6 7.7 Pev -10 9 Prostate 99.4 99.5 98.3 -10.0 9 Prostate 99.4 99.5 98.3 -10.0 9 Prostate 99.4 99.5 98.8 99.7 10 Ling 99.8 99.9 99.6 -10.0 -5 13 Waiva 90.0 93.8 97.7 -2 -2 13 Waiva <th>a a u lita i</th> <th></th> <th></th> <th>3%/3mm</th> <th>3%/2mm</th> <th>3%/3mm</th> <th>3%/2mm</th> <th></th> <th></th> <th>Case Site</th> <th>Passes</th>	a a u lita i			3%/3mm	3%/2mm	3%/3mm	3%/2mm			Case Site	Passes
2 Han 97.9 96.8 94.9 89.9 -3σ 3 Prostate 98.0 95.2 98.4 97.0 9 0 -5 4 HiAN 99.6 97.9 98.3 98.2 -5 -5 -5 5 Prostate 91.6 77.9 98.9 98.3 -10 -5 6 HiAN 99.6 98.7 99.3 98.2 -10 -15 -10 7 Pekin 98.6 99.7 99.3 98.6 97.9 93.3 -10 -10 9 Prostate 99.4 98.4 99.5 98.3 -10 -15 -10 -15 -10 -10 -15 -10 -5 0 -15 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10 -15 -10 -10	esuits:	1	H&N	99.4	96.6	99.9	99.7			Results:	
3 Prostate 98.0 95.2 98.4 97.0 4 HiRN 99.6 97.0 100 99.8 5 Prostate 91.6 77.9 98.9 98.3 6 HiRN 99.0 97.7 99.3 98.2 7 Pelvis 99.8 98.6 99.7 99.3 8 HiRN 99.6 99.7 99.3 9 Prostate 99.4 99.4 99.4 99.4 99.4 99.4 99.5 98.3 10 Lung 99.4 99.4 99.4 99.8 99.7 99.0 12 Exophagus 100 99.8 99.3 99.0 11 HiAN 90.7 99.9 99.0 13 W/W 99.0 99.0 99.0 99.0 13 W/W 99.0 99.0 99.0 14 HiAN 100 99.9 99.0 14 HiAN 100			H&N	97.9	96.8	94.9	89.9	-3 σ		2 H&N 97.9	, c
4 HāN 99.6 97.0 100 99.8 5 Prostate 91.6 77.9 98.9 98.3 6 HāN 99.0 97.9 99.3 98.2 7 Pelvis 99.8 98.6 99.7 99.3 8 HāN 99.6 98.7 99.6 99.0 9 Prostate 99.4 99.5 98.3 10 Lung 99.4 99.5 98.3 11 HāN 99.7 99.2 98.8 99.7 12 Exophagus 100 99.8 99.0 99.0 13 HāN 100 99.5 99.9 97.6 14 HāN 100 99.5 99.9 97.6			Prostate	98.0	95.2	98.4	97.0				0
5 Prostate 91,6 77,9 98,9 98,3 6 Hith 90,0 97,3 98,2 7 Pekiv 98,8 99,7 99,3 8 Hah 99,6 98,7 99,6 99,0 9 Prostate 99,4 99,5 98,3 10 Lung 9,4 98,8 99,9 11 Héh 99,7 99,2 98,8 11 Héh 99,7 99,2 98,8 12 Exophagus 100 99,8 94,3 13 Witw 99,0 99,3 96,6 14 Héh 100 99,5 99,9 13 Witw 99,0 99,3 96,6 14 Héh 100 99,5 99,9 96,6			H&N	99.6	97.0	100	99.8				-5
b ndr 97.0 97.3 99.2 99.2 7 Petrix Petrix -15 8 Hân 99.6 99.7 99.8 99.0 9 Prostate 99.4 99.5 98.3 10 Lung 94.4 99.5 98.3 11 Hān 90.7 92.2 98.8 90.7 12 Esophagus 100 99.8 94.3 91.8 -2σ 13 Vulva 99.0 98.0 93.3 96.7 14 Hah 100 99.5 99.0 70.6 70.7 14 Hah 100 99.8 99.3 97.6 70.6 70.7 13 Vulva 99.0 99.0 99.0 99.0 99.0 99.0 14 Hah 100 99.5 99.9 99.6 100 100 100			Prostate	91.6	77.9	98.9	98.3			5	-10
i Peros Prod Rod Prod <			Reluir	99.0	97.9	99.3	98.2				-15
9 Prostate 99.4 99.4 99.5 98.3 10 Lung 99.4 98.8 99.9 99.6 11 HáN 90.7 99.2 99.8 99.7 12 Exophagus 100 99.8 94.3 91.8 -2σ 13 Wide 99.0 99.0 -6 -6 -6 14 HáN 100 99.5 99.9 99.6 -6 -6			Han	99.6	98.7	99.6	99.0			8 HBN	-10 -5 0 5 10
10 Lung 99.4 98.8 99.9 99.6 11 H6A 90.7 99.2 99.8 90.7 12 Esophagus 100 99.8 94.3 91.8 -2σ 13 Vulva 99.0 98.0 99.3 96.7 14 H6N 100 99.5 99.9 99.6			Prostate	99.4	99.4	99.5	98.3			9 Prostate	Faile TL & Al
11 HBA 99.7 99.2 99.8 99.7 12 Exophagus 100 99.8 94.3 91.8 -2σ 13 Vulva 99.0 98.0 99.3 96.7 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 <			Lung	99.4	98.8	99.9	99.6			10 Lung	6
12 Esophagus 100 99.8 94.3 91.8 -2σ 13 Vulva 99.0 98.0 99.3 96.7 14 HāN 100 99.5 99.9 99.6			H&N	99.7	99.2	99.8	99.7			11 H&N	n in an in a some of the state of
13 Vulva 99.0 98.0 99.3 96.7 14 Han 100 99.5 99.9 99.6		12	Esophagus	100	99.8	94.3	91.8	-2 σ		12 Esophagus h	
14 HaN 100 99.5 99.9 99.6 Model During and Definition Suffrage			Vulva	99.0	98.0	99.3	96.7		Versant	13 Vulva 99.0	-• sar
			H&N	100	99.5	99.9	99.6		Medical Physics and Radiation Safety	14 H&N 100	



Using TG-218 in the Clinic

Conclusions

What's the effect on our clinical workflow?

Change	Average gamma passing rate			
Change	Old	New		
Gamma criteria (3%/3mm → 3%/2mm) (110 patient plans, PC method)	99.2	98.3		
Delivery method (PC \rightarrow TC) (15 select plans, 3%/2mm criteria)	98.4	97.6		

Where are we now?

• Adopted new gamma criteria, delivery method & practice limits, looking to begin using DVH-based analysis program



Thank you!

Brian Hasson, Ph.D. Charlie Geraghty, M.S. Texin Li, Ph.D. Lee Myers, Ph.D. Sandy Konerth, M.S.



References

• TG-218

Miften M, Olch A, Mihailidis D, Moran J, Pawlicki T, Molineu A, et al., "Tolerance limits and methodologies for IMRT measurementbased verification QA: recommendations of AAPM task group no. 218." Med Phys. 2018; 45(4):e53–e83.

• TG-120

D. A. Low, J. M. Moran, J. F. Dempsey, L. Dong, and M. Oldham, "Dosimetry tools and techniques for IMRT," Med. Phys. 2011; 38, 1313–1338.

TG-218 PowerPoint slide set

Miften, M. TG-218: How to Handle Pretreatment Measurement IMRT Verification QA [PowerPoint Slides]. Retrieved from http://amos3.aapm.org/abstracts/pdf/124-34859-405535-125518.pdf



Question 1

The TG-218 report provides comprehensive recommendations for a department's patient-specific IMRT/VMAT QA program. Select the best summary of recommendations for the following aspects: delivery method, gamma analysis criteria, low-dose threshold, universal tolerance limit, universal action limit.

a. Perpendicular Composite, 3%/2mm, 10%, 98%, 90%

- b. True Composite, 3%/2mm, 10%, 95%, 90%
- c. Perpendicular Field-by-Field, 3%/3mm, 10%, 90%, 80%

d. True Composite, 3%/3mm, 10%, 95%, 90%



Question 2

When a patient-specific IMRT/VMAT QA fails a given universal tolerance limit, what are the steps that a physicist should take?

- a. Ensure correct setup of measurement device.
- b. Ensure correct file transfer of plan from TPS to R&V system.
- c. Check the machine's daily QA results for output, flatness and symmetry.
- d. Deliver a standard field to verify the calibration of the measurement device.
- e. All of the above.

